Solara Active Pharma Sciences (SOLARA) Fundamentals 2026 — Revenue Analysis | SniperIQ
Solara Active Pharma Sciences (SOLARA) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹2,587 Crore, trading at ₹536.15 on the NSE. This SniperIQ fundamentals page covers Solara Active Pharma Sciences's valuation, profitability (net margin -0.5%), revenue (₹1,369 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Solara Active Pharma Sciences's market cap?
Solara Active Pharma Sciences (SOLARA) has a market capitalization of approximately ₹2,587 Crore, trading at ₹536.15 on the NSE. Market cap moves with the live share price.
What is Solara Active Pharma Sciences's P/E ratio?
Solara Active Pharma Sciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Solara Active Pharma Sciences?
Solara Active Pharma Sciences runs a net profit margin of -0.5%, a gross margin of 38.1%, and an operating margin of 6.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Solara Active Pharma Sciences generate?
Solara Active Pharma Sciences reported revenue of ₹1,369 Crore for fiscal year 2026, with net income of -₹7 Crore and earnings per share (EPS) of -1.68. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Solara Active Pharma Sciences pay a dividend?
Solara Active Pharma Sciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Solara Active Pharma Sciences financially healthy?
Solara Active Pharma Sciences carries a debt-to-equity ratio of 0.55x and a current ratio of 0.96x, with a market beta of 0.85. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Solara Active Pharma Sciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Solara Active Pharma Sciences (SOLARA) the key facts are: market cap ₹2,587 Crore, revenue ₹1,369 Crore, 52-week range 422-734.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Solara Active Pharma Sciences's full fundamentals live
Get Solara Active Pharma Sciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.